Clinical Scorecard: Acoramidis Linked to Lower Mortality Through 54 Months
At a Glance
| Category | Detail |
|---|---|
| Condition | Transthyretin Amyloid Cardiomyopathy |
| Key Mechanisms | Continuous acoramidis therapy reduces mortality and cardiovascular hospitalizations. |
| Target Population | Patients with transthyretin amyloid cardiomyopathy. |
| Care Setting | Multicenter clinical trial. |
Key Highlights
- 45% lower risk of all-cause mortality with continuous therapy.
- 49% lower risk of cardiovascular mortality compared to delayed initiation.
- 35% of patients on continuous therapy experienced first cardiovascular hospitalization vs 57% who switched.
- Smaller increases in N-terminal pro–B-type natriuretic peptide levels with continuous therapy.
- 94% of patients experienced treatment-emergent adverse events, with low discontinuation rates.
Guideline-Based Recommendations
Diagnosis
- Evaluate patients for transthyretin amyloid cardiomyopathy based on clinical presentation and biomarkers.
Management
- Initiate acoramidis therapy early and continue long-term for optimal outcomes.
Monitoring & Follow-up
- Assess functional capacity and biomarker levels regularly during treatment.
Risks
- Monitor for treatment-emergent adverse events, though long-term safety concerns were not identified.
Patient & Prescribing Data
389 patients who completed the parent study.
Continuous acoramidis treatment shows sustained benefits over delayed initiation.
Clinical Best Practices
- Encourage early initiation of acoramidis in eligible patients.
- Monitor patient responses and adjust treatment as necessary.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
